Neuralstem, Inc. (NASDAQ:CUR) rose to $6.06 per share in the last trading day compared to a prior close of $3.81. The management team hold 0.1 percent of the stock. Garr Richard ranks as top insider in Neuralstem, Inc., noted in the Company’s filings with the U.S. Securities and Exchange Commission. The insider’s stake of 1,449,804 shares is worth $8,785,812. Westreich Stanley is ranked No.2 with 1,564,854 shares as of Jul 01, 2015, which sits at a market value around $9,483,015. Johe Karl is another big name in this category. This insider owns 930,373 CUR shares, amounting to about $5,638,060 as of recent trading price which is 69.47% above its 20-day moving average and 36.26% above its 50-day moving average. The equity added 45.67% over the trailing 3 months.
Neuralstem, Inc. (NASDAQ:CUR), a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The companys stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke.
CEL-SCI Corporation (NYSEMKT:CVM) shares closed at $0.16, up 0.05 points or 38.86 percent from the previous close price. The up to date insider trading filings show CEO KERSTEN GEERT R has picked up 14,999 shares,upping the ownership to 6,659,605 units. The transaction occurred on Oct 13, 2014, at $0.77 per share worth a total $11,550. There was another major transaction on the insider-trading front. KERSTEN GEERT R, CEO at CVM bought 300,000 common shares at a per share price of $0.6 to hold 725,227 shares. The stock recently traded at a volume of 0 shares vs. an average volume of 1.77M. The latest closing price is now lower -43.21% for the past quarter. The price is now -10.84% below its 50-day moving average and -59.27% below its 200-day moving average. The percentage change return over the last fifty two weeks remained -58.16%. The price range in the same period had a highest hit of $0.66 while lowest level in that period was $0.06.
CEL-SCI Corporation (NYSEMKT:CVM) on December 20, 2016 announced that it has received net proceeds of $3,702,760 and expects to receive the remaining $75,000 this week from its previously announced public offering of common stock and warrants, after deducting estimated placement agent discounts and commissions and estimated offering expenses payable by the Company.
Pursuant to NYSE MKT Company Guide Section 610(b) disclosure requirements, CEL-SCI disclosed that its audited financial statements for the fiscal year ended September 30, 2016 included in its Form 10-K, filed with the Securities and Exchange Commission on December 14, 2016, contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern. This announcement does not represent any change or amendment to the Company’s financial statements or to its Annual Report on Form 10-K for the year ended September 30, 2016.